Supplementary Tables – Low dose sublingual fentanyl improves quality of life in patients with breakthrough cancer pain at Palliative Care

Supplementary Table 1. Low dose sublingual fentanyl improves quality of life in patients with breakthrough cancer pain at Palliative Care

Patient socio-demographic and clinical characteristics at baseline in the subpopulations treated with medium-to-high fentanyl doses (≥200μg) for BTcP.

Supplementary Table 2. Low dose sublingual fentanyl improves quality of life in patients with breakthrough cancer pain at Palliative Care

Clinical features of background pain and BTcP at baseline in the subpopulations treated with medium-to-high fentanyl doses (≥200μg) for BTcP

Supplementary Table 3. Low dose sublingual fentanyl improves quality of life in patients with breakthrough cancer pain at Palliative Care

Evolution of background pain and BTcP over the study period in the subpopulations treated with medium-to-high fentanyl doses (≥200μg) for BTcP.

Supplementary Table 4. Low dose sublingual fentanyl improves quality of life in patients with breakthrough cancer pain at Palliative Care

Quality of life outcomes according to the EORTC QLQ-C30 in the subpopulations treated with medium-to-high fentanyl doses (≥200μg) for BTcP.

Supplementary Table 5. Low dose sublingual fentanyl improves quality of life in patients with breakthrough cancer pain at Palliative Care

Global impression of improvement according to patient’s (PGI-I) and physician’s (CGI-I) perspective in the subpopulations treated with medium-to-high fentanyl doses (≥200μg) for BTcP.